Pearl Pai

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 122 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus et al. · Kidney International · 2021 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch

Meghan E. Murphy, David Reaich, Pearl Pai et al. · British Journal of Dermatology · 2003 · 74 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Successful Treatment of Encapsulating Peritoneal Sclerosis with Azathioprine and Prednisolone

Christopher F. Wong, Salah Beshir, Atif Ali Khan Khalil et al. · Peritoneal Dialysis International · 2005 · 50 citations

Pharmacy, Pathology, Pharmacotherapy +3